A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

Change From Baseline in Averaged Insulin Levels in Response to a Mixed-meal Tolerance Test

Change from baseline in averaged post prandial insulin levels in response to a mixed-meal tolerance test.

Time frame: After four weeks of active therapy

Change From Baseline in FFAs

Change from baseline in Free Fatty Acids (FFAs)following 28 days of active therapy, as part of a lipid profile assessment

Time frame: After 28 days of active therapy

Change From Baseline in Triglycerides

Change compared to baseline in triglycerides following 28 days of active therapy, as part of a lipid profile assessment

Time frame: 28 days

Change From Baseline in HDL

Change from baseline in HDL following 28 days of active therapy, as part of a lipid profile assessment

Time frame: 28 days